Key clinical point: Calaspargase pegol (SC-PEG) produces similar outcomes as standard pegaspargase in pediatric and young adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma.
Major finding: The 4-year event-free survival rate was 87.7% with SC-PEG and 90.2% with pegaspargase (P = .78). The 4-year overall survival rate was 94.8% and 95.6%, respectively (P = .74).
Study details: Phase 2 trial of 239 patients.
Disclosures: The trial was sponsored by the Dana-Farber Cancer Institute in collaboration with Shire and the National Cancer Institute. The speaker had no relationships to disclose.
Vrooman LM et al. ASCO 2019. Abstract 10006.